Supplemental Digital Content 2: Performance in mass and non-mass enhancing lesions.docx

The performance of both the full protocol model and the abbreviated protocol model showed no differences between mass and non-mass enhancing (NME) lesions.

|  |  |
| --- | --- |
| Figure 1. ROC curve of the full protocol model. In red the performance on all lesions, in green on the subset of mass enhancing lesions and in blue the performance of the model on NME lesions | Figure 2. ROC curve of the abbreviated protocol model. In red the performance on all lesions, in green on the subset of mass enhancing lesions and in blue the performance of the model on NME lesions |

For more detail we also show the DCA of the different lesion subsets. As shown in the table 1 and table 2, the performance measure of correctly classified benign BI-RADS 3 and 4 lesions is comparable to the overall performance of the model.

Table 1. DCA curve results of different subgroups of lesions, all lesions (top row), mass lesions (middle row) and NME lesions (bottom row) for both proposed models

|  |  |  |
| --- | --- | --- |
|  | Full protocol | Abbreviated protocol |
| All lesions | C:\Users\user\Documents\Paper2\Plaatjes\DCA_FULL.tif | C:\Users\user\Documents\Paper2\Plaatjes\DCA_SHORT.tif |
| Mass Lesions | C:\Users\user\Documents\Paper2\Indienen\Rebuttel\DCA_MASS_FULL.tif | C:\Users\user\Documents\Paper2\Indienen\Rebuttel\DCA_MASS_SHORT.tif |
| NME Lesions | C:\Users\user\Documents\Paper2\Indienen\Rebuttel\DCA_NME_FULL.tif | C:\Users\user\Documents\Paper2\Indienen\Rebuttel\DCA_NME_SHORT.tif |

Table 2. Overview of correctly classified benign BI-RADS 3 and 4 lesions for the subset of lesions and corresponding levels of correctly classified malignant lesions for both models. Results denote mean ± 1 standard deviation. Models were compared using the McNemar chi-square statistic.

|  |  |  |
| --- | --- | --- |
| Correctly classified malignant lesions | correctly classified benign BI-RADS 3 and 4 lesions |  |
|  | All lesions  |  |
|  | Full protocol |  | Abbreviated protocol |  |
| 100.0% | 41.5% ± 3.2% |  | 26.2% ± 3.2% | p<0.01 |
| 99.0% | 45.8% ± 3.5% |  | 36.6% ± 3.0% | p<0.01 |
| 95.0% | 52.4% ± 3.1% |  | 44.3% ± 3.6% | p<0.01 |
|  | Mass lesions  |  |
|  | Full protocol |  | Abbreviated protocol |  |
| 100.0% | 41.6% ± 3.7% |  | 27.6% ± 3.6%  | p<0.01 |
| 99.0% | 46.1% ± 3.8% |  | 37.3% ± 3.4% | p<0.01 |
| 95.0% | 52.1% ± 3.4% |  | 44.7% ± 3.6% | p<0.01 |
|  | NME lesions  |  |
|  | Full protocol |  | Abbreviated protocol |  |
| 100.0% | 41.2% ± 3.2% |  | 23.8% ± 4.8% | p<0.01 |
| 99.0% | 45.4% ± 5.5% |  | 35.3% ± 4.6% | p<0.01 |
| 95.0% | 52.8% ± 5.1% |  | 43.7% ± 5.5% | p<0.01 |